|Awarded On||August 20, 2014|
|Title||Realizing Personalized and Precision Medicine for Melanoma: A Rapid Assay for Measuring ERK Activity|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Kevin N Dalby|
Melanoma is a deadly form of skin cancer killing approximately ten thousand Americans per year, with a disproportionate number residing in Texas. Patients with melanoma have a poor prognosis, because while current targeted therapies are initially effective against the most common forms of melanoma containing a specific type of mutant BRAF kinase, their efficacy is limited by the near universal acquisition of resistance and resulting progressive disease. Our multi-disciplinary team at UT Austin, and MD Anderson has created a way to rapidly quantify the efficacy of current BRAF and MEK inhibitor therapies in melanoma cell lines. We have created a first-generation ERK sensor whose specificity a...